Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment.

Sylvain LehmannSusanna Schraen-MaschkeJean-Sébastien VidalConstance DelabyLuc BueeFrédéric BlancClaire PaquetBernadette AllinquantStéphanie BomboisAudrey GabelleOlivier Hanonnull null

Published in: Journal of neurology, neurosurgery, and psychiatry (2024)

Plasma pTau217 and pTau181 both correlate with AD, but the fold change in pTau217 makes it better to diagnose cerebral amyloidosis, and predict cognitive decline and conversion to AD dementia.

Keyphrases

mild cognitive impairment
cognitive decline
subarachnoid hemorrhage
cerebral ischemia
blood brain barrier